4-[4-(4-bromo-thiazol-2-yl)-pyrimidin-2-yl]-morpholine | 908141-89-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-[4-(4-bromo-thiazol-2-yl)-pyrimidin-2-yl]-morpholine
• 英文别名: 4-[4-(4-bromo-1,3-thiazol-2-yl)pyrimidin-2-yl]morpholine
• CAS: 908141-89-9
• 化学式: C₁₁H₁₁BrN₄OS
• 分子量: 327.205
• InChiKey: SOICUMGNBPPNFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  79.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-hydroxy-3,5-dimethoxyphenylboronic acid 、 4-[4-(4-bromo-thiazol-2-yl)-pyrimidin-2-yl]-morpholine 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 2,6-dimethoxy-4-[2-(2-morpholin-4-yl-pyrimidin-4-yl)-thiazol-4-yl]-phenol
  参考文献：
  名称：

  Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR

  摘要：

  A pharmacophore mapping approach, derived from previous experience of PIKK family enzymes, was used to identify a hit series of selective inhibitors of the mammalian target of rapamycin (mTOR). Subsequent refinement of the SAR around this hit series based on a tri-substituted triazine scaffold has led to the discovery of potent and selective inhibitors of mTOR. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.069
• 作为产物：
  描述：

  吗啉 、 4-(4-Bromo-thiazol-2-yl)-2-chloro-pyrimidine 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 0.17h， 以30.5%的产率得到4-[4-(4-bromo-thiazol-2-yl)-pyrimidin-2-yl]-morpholine
  参考文献：
  名称：

  Compounds

  摘要：

  化合物的化学式I： A-B-C  (I) 及其异构体、盐、溶剂合物、化学保护形式和前药，其中： B选自以下组合： 其中R N 为H或Me； 或B是含有一个或两个环异原子的二价C 5 杂环残基； A为： R A3 和R A5 独立选择自卤、OR O 和R AC ，其中R O 为H或Me，R AC 为H或C 1-4 烷基； X A 选自N和CR A4 ，其中R A4 选自H、OR O 、CH 2 OH、CO 2 H、NHSO 2 Me和NHCOMe； R A2 和R A6 独立选择自H、卤素和OR O ； 或R A3 和R A4 与它们连接的碳原子一起，或RA2和R A3 与它们连接的碳原子一起，可形成含有至少一个氮环原子的C 5-6 杂环或杂芳环； 如果X不是N，则R A2 至R A6 中的1、2或3个不是H； C为： 其中X选自N和CH，Y选自N和CH，Z选自N和CR C6 ； R C3 选自H、卤素和可选择性取代的含氮C 5-7 杂环基； R C5 为以下组合之一： 该组合可由一个或两个C 1-4 烷基或一个羧基选择； R C6 为H； 或者，当X和Y为N时，R C5 和R C6 （当Z为CR C6 时）与它们连接的碳原子可形成所选自的融合C 6 芳香环之一：

  公开号：

  US20060199804A1

文献信息

• Compounds
  申请人：Hummersone Geoffrey Marc

  公开号：US20060199804A1

  公开（公告）日：2006-09-07

  Compounds of formula I: A-B-C  (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of: where R N is H or Me; or B is a divalent C 5 heterocyclic residue containing one or two ring heteroatoms; A is: R A3 and R A5 are independently selected from halo, OR O and R AC , where R O is H or Me, and R AC is H or C 1-4 alkyl; X A is selected from N and CR A4 , where R A4 is selected from H, OR O , CH 2 OH, CO 2 H, NHSO 2 Me and NHCOMe; R A2 and R A6 are independently selected from H, halo and OR O ; or R A3 and R A4 together with the carbon atoms to which they are attached, or RA2 and R A3 together with the carbon atoms to which they are attached, may form a C 5-6 heterocylic or heteroaromatic ring, containing at least one nitrogen ring atom; where if X is not N, 1, 2, or 3 of R A2 to R A6 are not H; C is: where X is selected from N and CH, Y is selected from N and CH, and Z is selected from N and CR C6 ; R C3 is selected from H, halo and an optionally substituted N-containing C 5-7 heterocyclic group; R C5 is a group selected from: which group may be selected by one or two C 1-4 alkyl groups or a carboxy group; R C6 is H; or, when X and Y are N, R C5 and R C6 (when Z is CR C6 ) together with the carbon atoms to which they are attached may form a fused C 6 aromatic ring selected from the group consisting of:

  化合物的化学式I： A-B-C  (I) 及其异构体、盐、溶剂合物、化学保护形式和前药，其中： B选自以下组合： 其中R N 为H或Me； 或B是含有一个或两个环异原子的二价C 5 杂环残基； A为： R A3 和R A5 独立选择自卤、OR O 和R AC ，其中R O 为H或Me，R AC 为H或C 1-4 烷基； X A 选自N和CR A4 ，其中R A4 选自H、OR O 、CH 2 OH、CO 2 H、NHSO 2 Me和NHCOMe； R A2 和R A6 独立选择自H、卤素和OR O ； 或R A3 和R A4 与它们连接的碳原子一起，或RA2和R A3 与它们连接的碳原子一起，可形成含有至少一个氮环原子的C 5-6 杂环或杂芳环； 如果X不是N，则R A2 至R A6 中的1、2或3个不是H； C为： 其中X选自N和CH，Y选自N和CH，Z选自N和CR C6 ； R C3 选自H、卤素和可选择性取代的含氮C 5-7 杂环基； R C5 为以下组合之一： 该组合可由一个或两个C 1-4 烷基或一个羧基选择； R C6 为H； 或者，当X和Y为N时，R C5 和R C6 （当Z为CR C6 时）与它们连接的碳原子可形成所选自的融合C 6 芳香环之一：
• mTOR inhibitor compounds
  申请人：Kudos Pharmaceuticals Ltd.

  公开号：US07504397B2

  公开（公告）日：2009-03-17

  Compounds of formula I: A-B-C  (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof are provided, wherein variables A, B and C are defined herein and wherein such compounds act as mTor inhibitors.

  本文提供了公式I：A-B-C及其异构体、盐、溶剂合物、化学保护形式和前药，其中变量A、B和C在此定义，这些化合物作为mTor抑制剂。
• COMPOUNDS
  申请人：Hummersone Marc Geoffrey

  公开号：US20100130473A1

  公开（公告）日：2010-05-27

  Compounds of formula (I): A-B—C and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of formula (i) where R N is H or Me; or B is a divalent C 5 heterocyclic residue containing one or two ring heteroatoms; A is formula (ii) R A3 and R A5 are independently selected from halo, OR O and R AC , where R O is H or Me, and R AC is H or C 1-4 alkyl; X A is selected from N and CR A4 , where R A4 is selected from H, OR O , CH 2 OH, CO 2 H, NHSO 2 Me and NHCOMe; R A2 and R A6 are independently selected from H, halo and OR O ; or R A3 and R A4 together with the carbon atoms to which they are attached, or RA2 and R A3 together with the carbon atoms to which they are attached, may form a C 5-6 heterocylic or heteroaromatic ring, containing at least one nitrogen ring atom; where if X is not N, 1, 2, or 3 of R A2 to R A6 are not H; C is formula (iii) where X is selected from N and CH, Y is selected from N and CH, and Z is selected from N and CR C6 ; R C3 is selected from H, halo and an optionally substituted N-containing C 5-7 heterocyclic group; R C5 is a group selected from formula (iv) which group may be selected by one or two C 1-4 alkyl groups or a carboxy group; R C6 is H; or, when X and Y are N, R C5 and R C6 (when Z is CR C6 ) together with the carbon atoms to which they are attached may form a fused C 6 aromatic ring selected from the group consisting of formula (v).

  化合物的化学式（I）：A-B-C及其异构体，盐，溶剂合物，化学保护形式和前药，其中：B选自式（i）的群，其中RN为H或Me；或B是含有一个或两个环杂原子的二价C5杂环残基；A为式（ii）RA3和RA5分别独立选择自卤，ORO和RAC，其中RO为H或Me，而RAC为H或C1-4烷基；XA选自N和CRA4，其中RA4选自H，ORO，CH2OH，CO2H，NHSO2Me和NHCOMe；RA2和RA6分别独立选择自H，卤和ORO；或RA3和RA4与它们附着的碳原子一起，或RA2和RA3与它们附着的碳原子一起，可以形成一个含有至少一个氮环原子的C5-6杂环或杂芳烃环；如果XA不是N，则RA2至RA6中的1、2或3个不是H；C为式（iii）其中X选自N和CH，Y选自N和CH，Z选自N和CRC6；RC3选自H，卤和一个可选取代的含N的C5-7杂环基团；RC5是从式（iv）中选择的一个或两个C1-4烷基或羧基；RC6为H；或当X和Y为N时，RC5和RC6（当Z为CRC6时）与它们附着的碳原子一起可以形成所选自式（v）的群中的融合C6芳香环。
• HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS
  申请人：Kudos Pharmaceuticals Ltd

  公开号：EP1877388A2

  公开（公告）日：2008-01-16
• US7504397B2
  申请人：——

  公开号：US7504397B2

  公开（公告）日：2009-03-17